3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
81
Leukemia
33
Precursor Cell Lymphoblastic Leukemia-Lymphoma
25
Myelodysplastic Syndromes
22
Recurrence
13
Congenital Abnormalities
12
Lymphoma, Non-Hodgkin
9
Leukemia, Biphenotypic, Acute
9
Burkitt Lymphoma
9
Lymphoma, Mantle-Cell
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myelomonocytic, Chronic
7
Leukemia, Monocytic, Acute
7
Hodgkin Disease
7
Lymphoma
6
Leukemia, Myelomonocytic, Acute
6
Leukemia, Megakaryoblastic, Acute
6
Leukemia, Erythroblastic, Acute
6
Lymphoma, Large B-Cell, Diffuse
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Myeloproliferative Disorders
4
Lymphoma, Follicular
4
Lymphoma, B-Cell
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Leukemia, Prolymphocytic
3
Leukemia, Myeloid
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hematologic Neoplasms
3
Blast Crisis
3
Interventions
eltrombopag
1
durvalumab
1
Pemetrexed
1
Paclitaxel
1
Gemcitabine
1
Cytarabine
1
Cisplatin
1
Carboplatin
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pathologic Complete Response
×
Cytarabine
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts